Raphamin

Phase 3Small molecule

MMateria Medica Holding

Raphamin is one of 116 small molecule programs targeting Sinusitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

BronchitisRecruiting

PneumoniaActive, not recruiting

CystitisActive, not recruiting

SinusitisPhase 3

Active, not recruiting

BronchitisPhase 3

Recruiting

PneumoniaPhase 3

Active, not recruiting

CystitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Raphamin

MMateria Medica Holding

Phase 3

1 2

Primaxin

Pfizer

Preclinical

2 3

Innohep

Alnylam Pharmaceuticals

Preclinical

1 4

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 5

Retrovir

BBp Consulting, Inc

Preclinical

2 6

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Pepcid

KKenvue Brands

Preclinical

1 8

Aciphex

Akero Therapeutics

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Cystitis

NCT06284265

Q4 2027

Phase 3Recruiting

Efficacy and Safety

NCT06715891

Phase 3Recruiting

Sinusitis

NCT06901297

Q4 2028

Phase 3Recruiting

Bronchitis

NCT07650227

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

Completed·MMateria Medica Holding·Phase 3·NCT04918771·435 enrolled

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Recruiting·MMateria Medica Holding·Phase 3·NCT06715891·374 enrolled

Cystitis1 trial

Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis

Active, not recruiting·MMateria Medica Holding·Phase 3·NCT06284265·415 enrolled

Coronavirus Disease 20191 trial

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients

Completed·MMateria Medica Holding·Phase 3·NCT05364671·771 enrolled

Pneumonia1 trial

Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia

Completed·MMateria Medica Holding·Phase 3·NCT06263881·370 enrolled

Sinusitis1 trial

The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients

Recruiting·MMateria Medica Holding·Phase 3·NCT06901297·552 enrolled

1 more indication

Bronchitis1 trial

Multicenter, Double Blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients

Recruiting·MMateria Medica Holding·Phase 3·NCT07650227·308 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Raphamin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raphamin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raphamin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Materia Medica Holding company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMateria Medica Holding

Raphamin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Efficacy and Safety2 trials

Cystitis1 trial

Coronavirus Disease 20191 trial

Pneumonia1 trial

Sinusitis1 trial

Bronchitis1 trial

References

Drug Info

Quick Facts

Related News